GVK Biosciences and Onconova Therapeutics signs pact for cancer drugs

Details

Category: Contracts Research and Manufacturing

GVK Biosciences and Onconova Therapeutics has signed a pact to develop new drugs for cancer. The pact will facilitate to move oncology assets from Ocnonova Therapeutics to GVK discovery platform from early discovery to clinical development stage. As per the pact, Ocononova will provide two discovery targets for development of new drugs.

MSD and Hilleman Labs to set up research lab in Delhi

Details

Category: Contracts Research and Manufacturing

MSD, a unit of Merck Ltd is planning to set up a lab for developing vaccines in joint venture with Wellcome Trust Hilleman Laboratories (the Hilleman Labs - a London based research charity) in India. It will come up at Delhi Jamia Millia Islamia University campus and will entail an investment of USD 150 million. MSD has already developed a vaccine for rotavirus which has 90% efficiency against severe gastroenteritis. The lab will focus on vaccines for disease prevalent in tropical countries

Fortis to foray into full service clinical research

Details

Category: Contracts Research and Manufacturing

Fortis Clinical Research (FCRL), a Fortis Religare group company which so far functioning as an exclusive partner for Ranbaxy is venturing into full service clinical research. Currently, the global clinical research market is estimated at US$64 billion. Full service clinical research will include trials from phase I to phase III. Fortis has 48 hospitals across the country, while Super Religare Laboratories has 200 laboratories which will bring synergy in a full service clinical trials service. It has enjoyed patronage of pharma majors like Torrent, Unichem, IPCA, Ind-Swift, Panacea etc.,

Zydus Cadilla signs research agreement with Eli Lilly

Details

Category: Contracts Research and Manufacturing

Zydus Cadlila, the Ahmedabad based pharma company has signed agreement with Eli Lilly for conducting research on new drug discovery and development. The company will carry out research on discover and develop potential molecules in the area of cardiovascular research. It will initiate drug discovery, lead identification, optimization and then on pre-clinical trials. Eli Lilly will support the programme by providing feedback on chemistry, biology, toxicology, clinical and regulatory aspects.